- Head's hundred seals Australia win over England in 1st ODI after Labuschagne strikes
- Dream debut for Wirtz as Leverkusen thump dire Feyenoord
- Myanmar flood death toll climbs to 293: state media
- Israel army says West Bank air strike kills 4 militants
- LIV golfers get green light for US Ryder Cup team, PGA Championship
- US accuses social media giants of 'vast surveillance'
- Ten Hag to bed Hojlund, Mount in carefully when they return for Man Utd
- Breaking bad as McIlroy endures 'weird' day
- EU chief announces $11 bn for nations hit by 'heartbreaking' floods
- Spanish PM, Palestinian leader urge Mideast de-escalation
- New study reinforces theory Covid emerged at Chinese market
- World Bank boosts climate financing by 10 percent
- Bagnaia eyeing summit on home ground in 100th MotoGP
- 'Something was wrong', defendant in French mass rape tells court
- Hezbollah chief admits 'unprecedented' blow in device blasts
- Sales of US existing homes slip slightly in August
- Fear, panic haunt Lebanese after devices explode
- Labuschagne sparks Australia fightback in England ODI opener
- S.Africa's HIV research power couple says fight goes on
- Why is Israel focusing on border with Lebanon?
- Mpox vaccines administered in Rwanda, first in Africa
- US Fed rate cut is 'very positive sign' for economy: Yellen
- Unknown Mozart string trio discovered in Germany
- 'Are we five-year-olds?' F1 drivers won't mind their language
- Brazil judge orders X to reimpose block or face hefty fine
- Munich to rename stadium street after Beckenbauer
- Champions Italy to face Argentina in Davis Cup Final 8
- The winding, fitful path to weight loss drug Ozempic
- Italians defeat American Magic to reach Louis Vuitton Cup final
- Norris has 'nothing to lose' as he hunts Verstappen in Singapore
- Kyiv 'outraged' at Swiss showing of Russian war film
- French city renames Abbe Pierre square after abuse claims
- Footballer charged after huge cannabis seizure at UK airport
- Vatican recognises Medjugorje shrine, but not Virgin's messages
- Israel bombs Hezbollah strongholds in Lebanon after wave of deadly blasts
- Bank of England freezes rate after jumbo US cut
- Playing Nadal is 'kind of a nightmare', says Alcaraz
- Portugal tackles last of deadly northern forest fires
- Ton-up Ashwin lifts India to 339-6 against Bangladesh
- Departing NATO chief warns US against 'isolationism'
- Coming winter 'sternest test yet' for Ukraine energy grid
- Evacuations as tail of Storm Boris floods northeast Italy
- Lebanon's Hezbollah reeling after second wave of deadly blasts
- Taiwan recognises same-sex marriages between Chinese, Taiwanese
- Stock markets rally after jumbo US rate cut
- Gabon's ousted leader Bongo says renouncing politics for good
- Lebanon device blasts: what we know about deadly attacks
- Equity markets rally after jumbo US rate cut
- Late Harrods owner Al-Fayed accused of rape: BBC
- Hong Kong man sentenced 14 months for wearing 'seditious' T-shirt
RBGPF | 5.79% | 60.5 | $ | |
RYCEF | 5.76% | 6.95 | $ | |
JRI | -0.3% | 13.4 | $ | |
CMSC | -0.06% | 25.04 | $ | |
NGG | -1.68% | 68.89 | $ | |
RIO | 3.25% | 65.02 | $ | |
BCE | -1.04% | 35.245 | $ | |
SCS | -6.41% | 13.26 | $ | |
BCC | 4.59% | 143.65 | $ | |
CMSD | 0.13% | 25.012 | $ | |
RELX | 1.63% | 48.155 | $ | |
GSK | -1.29% | 41.89 | $ | |
VOD | -1.54% | 10.075 | $ | |
BTI | -0.77% | 37.59 | $ | |
AZN | 0.71% | 79.145 | $ | |
BP | 1.44% | 32.905 | $ |
WHO 'strongly recommends' Pfizer's Covid pill
The World Health Organization said Friday it "strongly recommended" Pfizer's Covid-19 antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalisation.
However the UN agency warned it was "extremely concerned" that the inequality in access seen with Covid vaccines would again leave low- and middle-income countries "pushed to the end of the queue".
US pharma giant Pfizer's combination of nirmatrelvir and ritonavir was the "superior choice" of treatment for unvaccinated, elderly or immunocompromised people with Covid, the WHO's experts said in the BMJ medical journal.
For the same patients, the WHO also made a "conditional (weak) recommendation" of the antiviral drug remdesivir made by US biotech firm Gilead -- which it had previously recommended against.
The WHO recommended Paxlovid over remdesivir, as well as over Merck's molnupiravir pill and monoclonal antibodies.
Pfizer's oral treatment prevents hospitalisation more than the "available alternatives, has fewer concerns with respects to harms than molnupiravir, and is easier to administer than intravenous remdesivir and antibodies," the WHO's experts said.
The new recommendation was based on the findings of two trials involving almost 3,100 patients which showed that Paxlovid reduced the risk of hospital admission by 85 percent.
The trials also "suggested no important difference in mortality" and "little or no risk of adverse effects leading to drug discontinuation".
The recommendation applies to people over the age of 18, but not to pregnant or breastfeeding women.
It also does not apply to patients with a low risk of complications from the disease, because the benefit would be minimal.
The WHO's experts also declined to give an opinion for patients with severe forms of the disease, due to a lack of data.
- Limitations and inequities -
The WHO stressed the limitations of such antiviral treatments.
"The medicine can only be administered while the disease is at its early stages," they said.
This means the patients must quickly test positive and be prescribed the pill by a doctor -- all of which can pose obstacles for low- and middle-income countries, the WHO said.
Yet Covid pills have been seen as a potentially huge step in ending the pandemic as they can be taken at home, rather than in hospital.
Patients must start taking their Paxlovid pills within five days of the onset of symptoms -- the course then lasts five days.
Remdesivir can be taken within seven days of symptoms setting in, but it is administered intravenously over three days.
- Questions about cost -
The WHO called on Pfizer to "make its pricing and deals more transparent" for Paxlovid.
Lisa Hedman, the WHO's senior advisor on access to medicines, said that radio station NPR reported a full course of Paxlovid costs $530 in the United States. Another source unconfirmed by WHO gave the price of $250 in an upper-middle income country.
Remdesivir meanwhile costs $520, Hedman said, but generic versions made by companies in India sell for $53-$64.
There is also a question mark over whether the virus could build resistance to these treatments.
But earlier this month Pfizer CEO Albert Bourla predicted a bright future for treatments like Paxlovid as people grow tired of getting further booster vaccinations.
Coming under fire for prioritising wealthy countries with its vaccine, Pfizer has agreed to allow some generic drugmakers around the world to make cheaper versions of Paxlovid under a UN-backed scheme.
But on Friday the WHO "strongly recommended" that Pfizer let more generic manufacturers produce the drug and "make it available faster at affordable prices".
F.Dubois--AMWN